中危重度主动脉瓣狭窄患者TAVR与SAVR的健康状态获益:PARTNER 2随机临床试验结果
PARTNER 2试验纳入2032例中危重度主动脉瓣狭窄患者,随机接受TAVR(Sapien XT瓣膜)或SAVR并随访2年。两组2年生存相似,健康状态均显著改善;TAVR仅在经股动脉入路患者中1个月时健康状态优于SAVR,1年和2年时无差异。
要点
- 中危重度AS患者TAVR与SAVR后2年健康状态均显著改善。
- TAVR早期健康状态优势仅见于经股动脉入路患者。
- 1年和2年时TAVR与SAVR健康状态无显著差异。
核心结论
- 中危重度AS患者接受TAVR或SAVR后2年内健康状态均显著改善。
- TAVR早期健康状态改善更优,但仅见于经股动脉入路患者。
- 1年和2年时TAVR与SAVR在任何健康状态指标上均无显著差异。
研究设计与样本
- 患者随机接受TAVR(Sapien XT瓣膜)或SAVR,随访2年。
- 主要分析队列为1833例有基线健康状态数据者(TAVR 950例,SAVR 883例)。
- 平均(SD)年龄81.4(6.8)岁,男性1006例(54.9%)。
主要发现
- 2年内TAVR和SAVR均与疾病特异性(KCCQ-OS量表16-22分)和通用健康状态(SF-36躯体摘要量表3.9-5.1分)显著改善相关。
- 1个月时经股动脉入路患者TAVR的KCCQ-OS平均差异为14.1分(95%CI 11.7-16.4,P<.01)。
- 1个月时经胸入路患者TAVR的KCCQ-OS平均差异为3.5分(95%CI -1.4至8.4,交互P<.01)。
- 1年和2年时TAVR与SAVR在任何健康状态指标上均无显著差异。
临床怎么用
- 中危重度AS患者选择TAVR或SAVR时,应告知两者2年健康状态获益相似。
- 经股动脉入路TAVR可能带来早期健康状态优势,可结合入路评估个体化决策。
局限性
- 需要更长期随访评估TAVR与SAVR生活质量改善的持久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with severe aortic stenosis (AS) at intermediate surgical risk, treatment with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) results in similar 2-year survival. The effect of TAVR vs SAVR on health status in patients at intermediate surgical risk is unknown. OBJECTIVE: To compare health-related quality of life among intermediate-risk patients with severe AS treated with either TAVR or SAVR. DESIGN, SETTING, AND PARTICIPANTS: Between December 2011 and November 2013, 2032 intermediate-risk patients with severe AS were randomized to TAVR with the Sapien XT valve or SAVR in the Placement of Aortic Transcatheter Valve 2 Trial and were followed up for 2 years. Data analysis was conducted between March 1, 2016, to April 30, 2017. MAIN OUTCOMES AND MEASURES: Health status was assessed at baseline, 1 month, 1 year, and 2 years using the Kansas City Cardiomyopathy Questionnaire (KCCQ) (23 items covering physical function, social function, symptoms, self-efficacy and knowledge, and quality of life on a 0- to 100-point scale; higher scores indicate better quality of life), Medical Outcomes Study Short Form-36 (36 items covering 8 dimensions of health status as well as physical and mental summary scores; higher scores represent better health status), and EuroQOL-5D (assesses 5 dimensions of general health on a 3-level scale, with utility scores ranging from 0 [death] to 1 [ideal health]). Analysis of covariance was used to examine changes in health status over time, adjusting for baseline status. RESULTS: Of the 2032 randomized patients, baseline health status was available for 1833 individuals (950 TAVR, 883 SAVR) who formed the primary analytic cohort. A total of 1006 (54.9%) of the population were men; mean (SD) age was 81.4 (6.8) years. Over 2 years, both TAVR and SAVR were associated with significant improvements in both disease specific (16-22 points on the KCCQ-OS scale) and generic health status (3.9-5.1 points on the SF-36 physical summary scale). At 1 month, TAVR was associated with better health status than SAVR, but this difference was restricted to patients treated via transfemoral access (mean difference in the KCCQ overall summary [KCCQ-OS] score, 14.1 points; 95% CI, 11.7 to 16.4; P < .01) and was not seen in patients treated via transthoracic access (mean difference in KCCQ-OS, 3.5 points; 95% CI, -1.4 to 8.4; P < .01 for interaction). There were no significant differences between TAVR and SAVR in any health status measures at 1 or 2 years. CONCLUSIONS AND RELEVANCE: Among intermediate-risk patients with severe AS, health status improved significantly with both TAVR and SAVR through 2 years of follow up. Early health status improvement was greater with TAVR, but only among patients treated via transfemoral access. Longer term follow-up is needed to assess the durability of quality-of-life improvement with TAVR vs SAVR in this population. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01314313.
引用
- Baron SJ, Arnold SV, Wang K, et al. Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER 2 Randomized Clinical Trial. JAMA Cardiol. 2017. PMID: 28658491. doi:10.1001/jamacardio.2017.2039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。